|Systematic (IUPAC) name|
|Biological half-life||20-23 hours|
|CAS Registry Number|
Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy.
- Mechanism of action 1
Approval history 2
- United States 2.1
- United Kingdom 2.2
- Indications and usage 3
- Dosing 4
- Side effects 5
- Drug interactions 6
- References 7
- External links 8
Mechanism of action
Felbamate has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit.     Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptors, the relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned.  Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.
- August 1993. Felbamate was approved for partial seizures with and without secondary generalization in adults and for Lennox-Gastaut Syndrome, a serious form of childhood epilepsy. Over the following year 150,000 people were started on felbamate therapy and a third of these became established.
- August 1, 1994. It was urgently withdrawn after 10 cases of aplastic anemia. A "Dear Doctor" letter was sent to 240,000 physicians.
- September 27, 1994. Felbamate had a limited redemption in another "Dear Doctor" letter sent to 260,000 physicians. It was recommended that the drug remain available only for patients with severe epilepsy for whom the benefits outweigh the risks, and that changes be made to the product's labelling to reflect the newly recognized risk. This redemption came with an additional warning since there had been 10 cases acute liver failure (4 of which were fatal). At this point, 10,000 to 12,000 people remained on the drug.
- The drug is only available on a limited named-patient basis.
Indications and usage
- Adults: Monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization.
- Children: Adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome.
Felbamate is available in tablets (400 mg and 600 mg) and as a peach-coloured oral suspension (600 mg/5 mL).
- Adults (> 14 years): begin with 1,200 mg daily given every 6 to 8 hours
- Children (2 > 14 years): 15 to 45 mg per kg per day given every 6 to 8 hours
Adverse reactions include decreased appetite, vomiting, insomnia, nausea, dizziness, somnolence, and headache. Many patients report increased alertness with the drug. Two rare but very serious effects include aplastic anemia and hepatic (liver) failure. The risk of aplastic anemia is between 1:3,600 and 1:5,000, of which 30% of cases are fatal. The risk of hepatic failure is between 1:24,000 to 1:34,000, of which 40% of cases are fatal.
Felbamate is an inhibitor of CYP2C19, an isoenzyme of the cytochrome P450 system involved in the metabolism of several commonly used medications. Felbamate interacts with several other AEDs, including phenytoin, valproate, and carbamazepine; dosage adjustments may be necessary to avoid adverse effects. Concomitant administration of felbamate and carbamazepine decreases blood levels of both drugs, while increasing the level of carbamazepine-10,11 epoxide, the active metabolite of carbamazepine.
- Rho JM, Donevan SD, Rogawski MA (March 1997). "Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate". J. Pharmacol. Exp. Ther. 280 (3): 1383–91.
- Leppik IE, Dreifuss FE, Pledger GW; et al. (November 1991). "Felbamate for partial seizures: results of a controlled clinical trial". Neurology 41 (11): 1785–9.
- Devinsky O, Faught RE, Wilder BJ; et al. (March 1995). "Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures". Epilepsy Res. 20 (3): 241–6.
- Rho JM, Donevan SD, Rogawski MA (Feb 1994). "Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors". Annals of Neurology 35 (2): 229–234.
- Kume A, Greenfield LJ, Macdonald RL, Albin RL (June 1996). "Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor". J. Pharmacol. Exp. Ther. 277 (3): 1784–92.
- Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA (May 1995). "Felbamate block of the N-methyl-D-aspartate receptor".
- Kleckner NW, Glazewski JC, Chen CC, Moscrip TD (May 1999). "Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action".
- Harty TP,Rogawski MA (March 2000). "Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit".
- Chang H-R, Chung-Chin Kuo C-C (March 2008). "Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor".
- Rogawski MA (March 2011). "Revisiting AMPA receptors as an antiepileptic drug target".
- "www.fda.gov". Retrieved 2008-11-15.
- "www.fda.gov". Retrieved 2008-11-15.
- Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Retrieved on December 25, 2008.
- Curry WJ, Kulling DL (February 1998). "Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin".
- Felbatol: Prescribing Information
- RxList: Felbamate contains extensive information including the patient warning and a sample consent form.
- Hard Choices with Felbamate
- Newer Antiepileptic Drugs: Gabapentin, Lamotrigine, Felbamate, Topiramate and Fosphenytoin
- MedPonte Pharmaceuticals